Key facts
- This page summarizes Andrea Liapis Jackson's Form 4/A - Amendment filing for Codex DNA, Inc. (TBIO).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Jun 2022, 16:35.
Andrea Liapis Jackson - 09 Jun 2022 Form 4/A - Amendment Insider Report for Codex DNA, Inc. (TBIO)
- Reporting relationship
- Director
- Issuer ticker
- TBIO
- Reported as of
- 09 Jun 2022
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 15 Jun 2022, 16:35:17 UTC
- Original report date
- 13 Jun 2022
- Prior SEC filing
- 17 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer McNealey, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrea Liapis Jackson filed Form 4/A - Amendment for Codex DNA, Inc. (TBIO) on 15 Jun 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 09 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TBIO
holding
Derivative
Stock Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 0
- Date
- 09 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 0
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
On June 9, 2022, the Reporting Person was granted 20,630 restricted stock units and options to purchase 30,945 shares of common stock of Codex DNA, Inc. (the "Issuer") under the Issuer's Outside Director Compensation Policy. However, the Reporting Person has declined the awards described above and any future annual awards until further notice. As a result, the transfer of such restricted stock units and options to purchase common stock did not in fact take place. Accordingly, as of June 15, 2022, the Reporting Person did not own any restricted stock units or options to purchase shares of common stock in the Issuer.